Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respira...
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
About this item
Full title
Author / Creator
Fleming-Dutra, Katherine E. , Jones, Jefferson M. , Roper, Lauren E. , Prill, Mila M. , Ortega-Sanchez, Ismael R. , Moulia, Danielle L. , Wallace, Megan , Godfrey, Monica , Broder, Karen R. , Tepper, Naomi K. , Brooks, Oliver , Sánchez, Pablo J. , Kotton, Camille N. , Mahon, Barbara E. , Long, Sarah S. and McMorrow, Meredith L.
Publisher
United States: U.S. Government Printing Office
Journal title
Language
English
Formats
Publication information
Publisher
United States: U.S. Government Printing Office
Subjects
More information
Scope and Contents
Contents
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant...
Alternative Titles
Full title
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578951
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578951
Other Identifiers
ISSN
0149-2195
E-ISSN
1545-861X
DOI
10.15585/mmwr.mm7241e1
